UCB Seeks Approval for New Crohn's Disease Treatment
Posted on: Friday, 3 March 2006, 09:00 CST
Biopharmaceutical firm UCB has submitted an application to the FDA seeking approval for Cimzia for the treatment of patients with Crohn's disease.
If approved, Cimzia (certolizumab pegol, CDP870) would be the first-ever biologic utilizing subcutaneous injection for the treatment of Crohn's disease. It is the first and only PEGylated Fab' fragment of a humanized anti-TNF alpha antibody.
The application includes safety and efficacy data from well-controlled clinical trials in more than 1,500 patients with Crohn's disease. The pivotal studies met their primary endpoints by demonstrating that Cimzia induced and maintained a clinical response in a significant percentage of patients.
UCB says the Cimzia license application represents the largest biologic clinical trial database and broadest, in terms of patient types, submitted to the FDA for Crohn's disease treatment.
"There are significant unmet needs among Crohn's patients, so additional therapeutic agents will increase our ability to provide effective long-term relief from this debilitating disease," commented Dr William Sandborn, professor of medicine at the Mayo Clinic College of Medicine and a leading investigator in the Cimzia clinical trial program.
In addition to the completed and ongoing studies in Crohn's disease, Cimzia studies are also ongoing in the treatment of rheumatoid arthritis and psoriasis. The company also plans to market the product in Europe.
Source: Datamonitor
Related Articles
- Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies With REOLYSIN(R)
- UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Presented at American Society for Dermatologic Surgery Annual Meeting
- Spaulding Rehabilitation Hospital Enrolls First Patient in a Clinical Study of New Neurotechnology For Stroke Rehabilitation
- Theravance Announces Positive Results From Phase 2 Clinical Study in Chronic Constipation With Investigational Compound TD-5108
- St. Paul Heart Clinic Seeks Heart Failure Patients for Investigational Study Evaluating Use of New Implantable Pulse Generator
- St. Francis Hospital Seeks Heart Failure Patients for Investigational Study Evaluating Use of New Implantable Pulse Generator
- Newark Beth Israel Medical Center Seeks Heart Failure Patients for Investigational Study Evaluating Use of New Implantable Pulse Generator
- Romark Laboratories Announces Clinical Study Evaluating Alinia(R) for Treatment of Crohn's Disease
- California Pacific Medical Center Seeks Heart Failure Patients for Investigational Study Evaluating Use of New Implantable Pulse Generator
- U. Enlists Patients in Clinical Study Linked to Fatal Lung Disease
 |
 |
User Comments (0)
RSS Feeds